Forums » News

• Topic
• Posted By
• Last Post
• Replies

• FDA concludes that Rotarix is safe to use
• Paul
• 17th May, 10:37
• 0

• Astellas to acquire OSI for $4bn
• Paul
• 17th May, 10:36
• 0

• Pfizer extends agreement with Strides Arcolab
• Paul
• 14th May, 16:47
• 0

• FDA approves Dr Reddy’s tacrolimus
• Paul
• 14th May, 16:46
• 0

• Expert panel says FDA needs new standards
• Paul
• 14th May, 10:40
• 0

• FDA rejects Teva petition on Copaxone
• Paul
• 14th May, 10:40
• 0

• Sanofi and Merck selling veterinary units
• Paul
• 13th May, 16:57
• 0

• FDA halts ELEVATE trial for Promacta
• Paul
• 13th May, 11:01
• 0

• NicOx shares plummet as FDA refuses approval of naproxcinod
• Paul
• 13th May, 11:01
• 0

• Daiichi Sankyo sees 13% sales growth
• Paul
• 12th May, 17:19
• 0

• Pfizer licenses novel PAH treatment from Ergonex
• Paul
• 12th May, 17:19
• 0

• Takeda to cut 1,400 jobs, sees profits slide
• Paul
• 12th May, 17:18
• 0

• Ranbaxy enjoys first quarter profits of $213m
• Paul
• 12th May, 13:51
• 0

• Abbott announces deal with Zydus Cadila
• Paul
• 12th May, 13:46
• 0

• Merck to file for five new drugs in 2010
• Paul
• 12th May, 13:46
• 0

• Gilead announces $5bn stock repurchase
• Paul
• 11th May, 19:45
• 0

• Pfizer to move 1,400 out of New York
• Paul
• 11th May, 19:44
• 0

• GlaxoSmithKline signs South Korean alliance
• Paul
• 11th May, 19:43
• 0

• Study shows heartburn drugs increase risk of bone fractures
• Paul
• 11th May, 12:35
• 0

• Takeda allies with Janssen over Velcade in Japan
• Paul
• 10th May, 17:43
• 0

• Ferring acquires rights to Lysteda from Xanodyne
• Paul
• 10th May, 17:42
• 0

• Teva ordered to pay $356m in damages
• Paul
• 10th May, 09:59
• 0

• Pig virus DNA found in RotaTeq vaccine
• Paul
• 07th May, 17:49
• 0

• FDA approves Bayer’s oral contraceptive
• Paul
• 07th May, 10:44
• 0

• Genzyme mulls stock repurchase and spin offs
• Paul
• 07th May, 10:43
• 0

• Aeterna’s ovarian cancer treatment gets orphan status
• Paul
• 06th May, 17:58
• 0

• Endo Pharmaceuticals to buy HealthTronics for $223m
• Paul
• 06th May, 17:57
• 0

• Lundbeck has “very good start” to 2010
• Paul
• 06th May, 08:18
• 0

• Smith & Nephew posts healthy Q1
• Paul
• 06th May, 08:16
• 0

• Merck acquires Ariad cancer drug
• Paul
• 05th May, 17:13
• 0

• NHS considering unlicensed eye drug
• Paul
• 05th May, 17:13
• 1

• Intermune’s lung drug rejected by FDA
• Paul
• 05th May, 17:13
• 0

• FDA slams J&J manufacturing plant
• Paul
• 05th May, 17:12
• 0

• Suicide risk “similar” for all antidepressants
• Paul
• 05th May, 14:32
• 0

• No approval from FDA for Stedesa
• Paul
• 05th May, 14:31
• 0

• Pfizer pleases analysts, sticks to forecast for 2010
• Paul
• 04th May, 18:14
• 0

• Schering acquisition weighs on Merck profits
• Paul
• 04th May, 18:13
• 0

• Teva profits rise to $830 million in Q1
• Paul
• 04th May, 11:34
• 0

• FDA reviews safety of prostate cancer drugs
• Paul
• 04th May, 11:33
• 0

• Sanofi enters pain deal with Glenmark
• Paul
• 03rd May, 17:15
• 0

• FDA delays decision on Bristol’s belatacept
• Paul
• 03rd May, 17:14
• 0

• Positive results continue for taspoglutide
• Paul
• 30th April, 15:50
• 0

• Provenge cancer vaccine gets US approval
• Paul
• 30th April, 15:37
• 0

• Tarceva approved in EU for new role in lung cancer
• Paul
• 30th April, 09:09
• 0

• Crestor lifts AZ first quarter results
• Paul
• 30th April, 08:59
• 0

• BMS reports positive Q1 but cuts outlook
• Paul
• 30th April, 08:35
• 0

• Study suggests lower lung cancer survival in England
• Paul
• 29th April, 08:31
• 0

• Merck shuffles top management
• Paul
• 29th April, 08:30
• 0

• Sanofi sees good Q1 and maintains 2010 forecast
• Paul
• 29th April, 08:29
• 0

• Roche’s Lucentis helps eyesight in diabetics
• Paul
• 28th April, 15:30
• 0

• FDA denies Salix drug over manufacturing issues
• Paul
• 28th April, 15:29
• 0

• GSK posts strong Q1 but raises EU drug pricing concerns
• Paul
• 28th April, 15:26
• 0

• Merck KGaA triples profits in Q1
• Paul
• 28th April, 15:25
• 0

• Novo provides an optimistic outlook for 2010
• Paul
• 27th April, 18:04
• 0

• Bayer plans on tenfold Chinese market growth
• Paul
• 27th April, 18:04
• 0

• AstraZeneca to pay $520 million over Seroquel case
• Paul
• 27th April, 18:03
• 0

• Crestor approved for broader use in EU
• Paul
• 27th April, 10:00
• 0

• Amgen appoints Bradway as COO
• Paul
• 27th April, 09:40
• 0

• Pfizer wins to block generic Protonix
• Paul
• 26th April, 16:21
• 0

• Charles River buys WuXi in $1.6bn deal
• Paul
• 26th April, 09:52
• 0

• Nycomed and Merck collaborate on Daxas
• Paul
• 26th April, 09:37
• 0

• Pfizer halts trial after Sutent underperforms
• Paul
• 23rd April, 16:22
• 0

• Seroquel XR gets EU recommendation for depression
• Paul
• 23rd April, 16:08
• 0

• Europe gives Daxas the green light
• Paul
• 23rd April, 15:56
• 0

• European ruling bolsters UK generics
• Paul
• 23rd April, 11:32
• 0

• Novartis gets US approval for Zortress
• Paul
• 22nd April, 13:49
• 0

• Reinhardt takes the reins at Bayer Healthcare
• Paul
• 22nd April, 09:24
• 0

• Pfizer warned over child study
• Paul
• 21st April, 17:00
• 0

• Genzyme faces $175m fine over manufacturing issues
• Paul
• 21st April, 16:48
• 0

• Drug companies lower forecasts on healthcare legislation
• Paul
• 21st April, 16:39
• 0

• Benlysta disappoints in lupus trials
• Paul
• 21st April, 07:26
• 0

• Novartis strikes $467m deal as Q1 profit rises 49%
• Paul
• 20th April, 16:58
• 0

• Tamoxifen and Evista show long term cancer benefit
• Paul
• 20th April, 09:52
• 0

• Novartis withdraws EU hepatitis drug submission
• Paul
• 20th April, 09:33
• 0

• IMS sees $1.1 trillion drug market by 2014
• Paul
• 20th April, 09:18
• 0

• Elan considers splitting business
• Paul
• 19th April, 19:07
• 0

• Stallergenes reports positive late-stage results for Oralair
• Paul
• 19th April, 09:13
• 0

• Astellas bullish as OSI sees further Tarceva approval
• Paul
• 19th April, 09:03
• 0

• Former Novartis CEO joins Baxter
• Paul
• 16th April, 15:53
• 0

• Sanofi and BMS pursue $442m damages over generic Plavix
• Paul
• 16th April, 09:56
• 0

• Novartis loses US CEO and over 300 jobs
• Paul
• 15th April, 16:24
• 0

• Celgene partners with Agios on cancer metabolism
• Paul
• 15th April, 16:08
• 0

• Roche beats Q1 expectations on cancer sales
• Paul
• 15th April, 09:50
• 0

• Sanofi reveals positive diabetes results
• Paul
• 15th April, 09:38
• 0

• Genzyme welcomes good news on Campath
• Paul
• 14th April, 18:34
• 0

• Baxter’s Gammagard shows promise in dementia
• Paul
• 14th April, 10:09
• 0

• Abraxis reportedly considering sale
• Paul
• 13th April, 18:31
• 0

• J&J sees FDA approval for Pancreaze
• Paul
• 13th April, 18:16
• 0

• Teva strikes $334m oncology deal with Mersana
• Paul
• 13th April, 18:06
• 0

• Roche acquires insulin delivery player Medingo
• Paul
• 13th April, 08:48
• 0

• Abbott emails requested over Depakote investigation
• Paul
• 13th April, 08:33
• 0

• Hospira trumps Myriad in bid for Javelin
• Paul
• 12th April, 16:58
• 0

• Novartis and Roche threaten UK exodus, Guardian reports
• Paul
• 12th April, 15:52
• 0

• FDA concerned over cancer risk with Byetta
• Paul
• 12th April, 09:30
• 0

• Merck KGaA defends Millipore acquisition
• Paul
• 09th April, 15:44
• 0

• FDA issues response on pixantrone
• Paul
• 09th April, 15:31
• 0

• Celgene sees early success with stem cells
• Paul
• 09th April, 10:19
• 0

• Celgene looks beyond cancer
• Paul
• 08th April, 16:38
• 0

• Sanofi and CureDM in $335m diabetes deal
• Paul
• 08th April, 09:52
• 0

• FDA panel delivers body blow to Daxas
• Paul
• 08th April, 09:41
• 0

• Teva wins first approval for generic Cozaar and Hyzaar
• Paul
• 07th April, 16:05
• 0

• Pfizer looks to the East, expects more blockbusters
• Paul
• 07th April, 15:51
• 0

• Five a day benefit queried in cancer prevention
• Paul
• 07th April, 06:45
• 0

• UK agrees deal on surplus flu vaccine
• Paul
• 07th April, 06:30
• 0

• Fast track granted for two cancer drugs
• Paul
• 06th April, 16:37
• 0

• GSK and Crucell join forces in malaria fight
• Paul
• 06th April, 09:39
• 0

• US regulators question Daxas benefits
• Paul
• 05th April, 16:46
• 0

• NICE takes positive view on Alimta
• Paul
• 05th April, 09:46
• 0

• US prescription sales grow 5.1% in 2009
• Paul
• 02nd April, 11:47
• 0

• FDA queries safety of Stalevo
• Paul
• 01st April, 18:08
• 0

• Sanofi settles Eloxatin dispute
• Paul
• 01st April, 17:55
• 0

• Pfizer opens up on physician payments
• Paul
• 01st April, 07:30
• 0

• New study defends breast cancer screening benefits
• Paul
• 01st April, 07:18
• 0

• Sanofi invests in devices and biotech manufacturing
• Paul
• 31st March, 16:07
• 0

• GSK and Isis ink $1.5bn antisense deal
• Paul
• 31st March, 15:50
• 0

• Xeloda approved for earlier colon cancer use
• Paul
• 31st March, 10:17
• 0

• Glaxo’s Duodart approved in Europe
• Paul
• 31st March, 10:04
• 0

• TNFerade fails in pancreatic cancer
• Paul
• 30th March, 15:57
• 0

• Nuvigil fails to get approval for jet lag
• Paul
• 30th March, 10:07
• 0

• NICE changes its mind on Multaq
• Paul
• 30th March, 09:58
• 0

• GSK looks to Japan for SME opportunity
• Paul
• 29th March, 10:06
• 0

• Antisoma’s lead cancer drug fails in phase III
• Paul
• 29th March, 09:46
• 0

• EMA backs continued use of Rotarix
• Paul
• 26th March, 18:51
• 0

• Congress gives healthcare reform the green light
• Paul
• 26th March, 08:45
• 0

• US approval of Xifaxan bolsters Salix
• Paul
• 25th March, 17:24
• 0

• Is page 1,617 a NICE addition to healthcare reform?
• Paul
• 25th March, 12:11
• 0

• Danish study shows no impact from breast cancer screening
• Paul
• 25th March, 12:02
• 0

• New dual anti-clotting agent approved in Europe
• Paul
• 24th March, 20:21
• 0

• GSK and Pfizer collaborate on vaccines deal
• Paul
• 24th March, 20:09
• 0

• Obama signs healthcare reform into law
• Paul
• 24th March, 09:56
• 0

• Rotarix vaccine suspended on contamination fears
• Paul
• 23rd March, 11:12
• 0

• Adverse event halts Stimuvax cancer trial
• Paul
• 23rd March, 04:20
• 0

• Pixuvri gets unanimous no for NHL
• Paul
• 22nd March, 17:02
• 0

• Glaxo’s Avandia suspended in Saudi Arabia
• Paul
• 22nd March, 16:40
• 0

• Biogen reaches detente with Icahn
• Paul
• 22nd March, 16:29
• 0

• Sanofi’s Multaq faces pricing hurdle in France
• Paul
• 22nd March, 10:25
• 0

• Obama gets healthcare reform through the House
• Paul
• 22nd March, 09:30
• 0

• OSI gets positive EU opinion for Tarceva
• Paul
• 19th March, 20:25
• 0

• Novartis gets EU approval for Menveo vaccine
• Paul
• 19th March, 11:17
• 0

• Takeda withdraws EU diabetes application
• Paul
• 19th March, 10:27
• 0

• AstraZeneca wins first Seroquel trial
• Paul
• 18th March, 16:45
• 0

• Teva seals Ratiopharm deal for $5bn
• Paul
• 18th March, 16:30
• 0

• Roche aims for six launches in next four years
• Paul
• 18th March, 11:31
• 0

• Abraxis lung cancer drug succeeds in phase III
• Paul
• 17th March, 16:25
• 0

• IMS says 48% of growth to come from emerging markets
• Paul
• 17th March, 10:42
• 0

• Tekturna trial shows no benefit post heart attack
• Paul
• 16th March, 19:51
• 0

• OSI rejects takeover bid, Astellas responds
• Paul
• 16th March, 11:52
• 0

• FDA requires more time to decide on Bydureon
• Paul
• 15th March, 17:27
• 0

• Former Schering-Plough execs move into Bausch
• Paul
• 15th March, 16:39
• 0

• Plavix gets new warning in the US
• Paul
• 15th March, 16:25
• 0

• Disappointing drug results for diabetes patients
• Paul
• 15th March, 10:40
• 0

• Study shows health benefits of the pill
• Paul
• 12th March, 17:39
• 0

• Avastin fails in advanced prostate cancer
• Paul
• 12th March, 12:45
• 0

• Pfizer see two late-stage cancer failures
• Paul
• 12th March, 12:21
• 0

• J&J asks for second opinion on ceftobiprole
• Paul
• 11th March, 17:18
• 0

• AstraZeneca strikes Indian generics deal
• Paul
• 11th March, 09:51
• 0

• Novartis in cancer vaccine deal worth almost $1bn
• Paul
• 10th March, 16:57
• 0

• Botox approved in US for upper limb spasticity
• Paul
• 10th March, 16:45
• 0

• Intermune gets FDA recommendation for Esbriet
• Paul
• 10th March, 16:29
• 0

• Abbott acquires Facet, trumps Biogen bid
• Paul
• 10th March, 10:58
• 0

• Cerepro MAA withdrawn, Ark considers sale
• Paul
• 09th March, 19:10
• 0

• UK regulators see breach of ethics on Seroquel
• Paul
• 09th March, 10:58
• 0

• Sanofi, Merck and Lilly in animal health shake up
• Paul
• 09th March, 10:40
• 0

• Recentin fails in late-stage cancer trial
• Paul
• 08th March, 17:30
• 0

• Roche and Biogen suspend ocrelizumab development
• Paul
• 08th March, 10:22
• 0

• GSK could face $6bn liability over Avandia
• Paul
• 08th March, 10:13
• 0

• Intermune gets reprieve from FDA on lung drug
• Paul
• 05th March, 16:35
• 0

• Major OSI shareholder asks Astellas for 15% more
• Paul
• 05th March, 16:14
• 0

• ADVANCE-2 trial show positive results for apixaban
• Paul
• 05th March, 10:45
• 0

• BMS bullish about 2013 and beyond
• Paul
• 04th March, 22:35
• 0

• Cipralex soars but Lundbeck misses Q4 profit forecast
• Paul
• 04th March, 10:28
• 0

• NICE says no to Celgene’s Vidaza
• Paul
• 04th March, 09:59
• 0

• Dimebon fails to live up to early promise in dementia
• Paul
• 03rd March, 17:38
• 0

• Andreotti takes the helm at BMS
• Paul
• 03rd March, 10:56
• 0

• Race for Ratiopharm enters the final stages
• Paul
• 03rd March, 10:32
• 0

• AstraZeneca closes UK R&D sites
• Paul
• 02nd March, 18:34
• 0

• UCB looks to Cimzia and Vimpat for growth
• Paul
• 02nd March, 10:43
• 0

• Belatacept gets recommendation from FDA panel
• Paul
• 02nd March, 10:29
• 0

• Actelion investors disappointed after bosentan failure
• Paul
• 01st March, 17:17
• 0

• AstraZeneca takes back US rights from Merck
• Paul
• 01st March, 17:03
• 0

• Baxter announces acquisition of ApaTech for $330m
• Paul
• 01st March, 16:49
• 0

• Astellas makes a move on OSI
• Paul
• 01st March, 16:34
• 0

• Merck KGaA acquiring Millipore for $7.2bn
• Paul
• 01st March, 10:22
• 0

• Bayer Healthcare grows on emerging markets
• Paul
• 27th February, 20:13
• 1

• Agreement in short supply during healthcare summit
• Paul
• 26th February, 17:58
• 0

• FDA weighs up safety ahead of belatacept decision
• Paul
• 26th February, 17:36
• 0

• Lundbeck announces positive results for stroke drug
• Paul
• 26th February, 08:59
• 0

• Obama kicks off US healthcare reform summit
• Paul
• 25th February, 16:37
• 0

• Lilly looks to R&D innovation as generics loom
• Paul
• 25th February, 16:24
• 0

• Avastin shows promise in ovarian cancer
• Paul
• 25th February, 10:27
• 0

• Pfizer gets FDA approval for Prevnar 13
• Paul
• 24th February, 17:27
• 0

• Basilea strikes deal with Astellas
• Paul
• 24th February, 11:31
• 0

• Xeloda recommended for expanded use in EU
• Paul
• 24th February, 10:52
• 0

• Big pharma join forces to tackle cancer
• Paul
• 23rd February, 16:31
• 0

• AstraZeneca settles UK tax issues, raises 2010 guidance
• Paul
• 23rd February, 16:30
• 0

• FDA approves Gilead’s inhaled antibiotic
• Paul
• 23rd February, 16:29
• 0

• Avastin fails in stomach cancer trial
• Paul
• 23rd February, 11:33
• 0

• Merck KGaA disappoints with 2010 forecast
• Paul
• 23rd February, 11:10
• 0

• Obama seeks to reignite healthcare reform
• Paul
• 22nd February, 18:57
• 0

• Icahn seeks board position at Genzyme
• Paul
• 22nd February, 17:36
• 0

• FDA approves meningitis vaccine
• Paul
• 22nd February, 17:36
• 0

• Avandia comes under fire from US Senators
• Paul
• 22nd February, 08:33
• 0

• FDA grants priority review for Tasigna
• Paul
• 19th February, 18:20
• 0

• Shire gains on strong Q4 Adderall XR sales
• Paul
• 19th February, 17:55
• 0

• EMA gives GlaxoSmithKline the green light on cancer drugs
• Paul
• 19th February, 17:34
• 0

• Rituxan gets US approval for CLL
• Paul
• 19th February, 11:45
• 0

• Europe issues negative opinion on superbug antibiotic
• Paul
• 19th February, 11:25
• 0

• FDA warning for long term asthma treatments
• Paul
• 19th February, 08:58
• 0

• Biogen extends hemophilia agreement
• Paul
• 18th February, 16:25
• 0

• Stay happy and reduce heart disease
• Paul
• 18th February, 11:09
• 0

• FDA rejects GSK / Xenoport Restless Legs drug
• Paul
• 18th February, 11:09
• 0

• Manufacturing woes impact Genzyme’s results
• Paul
• 17th February, 16:50
• 0

• Study suggests potential diabetes risk from statins
• Paul
• 17th February, 16:49
• 0

• FDA approves ESA risk management program
• Paul
• 17th February, 09:19
• 0

• Abbott acquisition of Solvay closes
• Paul
• 17th February, 09:19
• 0

• Merck tops expectations in 2009 results
• Paul
• 16th February, 17:08
• 0

• Teva posts $13.9bn record sales in 2009
• Paul
• 16th February, 14:11
• 0

• UK drug exports threaten patient safety
• Paul
• 16th February, 14:10
• 0

• $14bn European internet Rx market bypasses doctors
• Paul
• 16th February, 10:54
• 0

• AstraZeneca licenses arthritis drug in potential $1.2bn deal
• Paul
• 16th February, 10:43
• 0

• Victoza wins NICE approval for diabetes
• Paul
• 15th February, 11:10
• 0

• Alcon committee use 2009 results to highlight “inadequacy” of Novartis bid
• Paul
• 15th February, 11:09
• 0

• Tauzin steps down as head of PhRMA
• Paul
• 12th February, 16:18
• 0

• AstraZeneca plays the long game
• Paul
• 12th February, 16:17
• 0

• Cephalon optimistic for 2010
• Paul
• 12th February, 10:33
• 0

• European Commission clears Abbott, Solvay deal
• Paul
• 12th February, 10:33
• 0

• Pharma embraces new technology to reach patients
• Paul
• 11th February, 19:25
• 0

• Mipomersen meets endpoint but safety concerns remain
• Paul
• 11th February, 19:24
• 0

• Roche announces more good news for taspoglutide
• Paul
• 11th February, 15:59
• 0

• Benicar approved for high blood pressure in children
• Paul
• 11th February, 15:32
• 0

• Merck seeks closure on Vioxx saga
• Paul
• 11th February, 10:12
• 0

• [sticky] Website feedback
• Paul
• 10th February, 22:26
• 4

• Boehringer completing acquisition of SSP
• Paul
• 10th February, 16:54
• 0

• Reckitt declares 2009 “a very good year”
• Paul
• 10th February, 16:37
• 0

• Sanofi shows strong growth in 2009
• Paul
• 10th February, 10:38
• 0

• First stem cell clinical trial gets the green light
• Paul
• 10th February, 09:38
• 0

• Amgen's bone drug outperforms Novartis rival in trial
• Paul
• 09th February, 18:18
• 0

• Biogen bullish on positive fourth quarter results
• Paul
• 09th February, 18:03
• 0

• GSK closing UK research site
• Paul
• 09th February, 17:47
• 0

• FDA approves Crestor for new indication
• Paul
• 09th February, 10:03
• 0

• NICE rules on Novartis, BMS cancer drugs
• Paul
• 09th February, 09:52
• 0

• Could consolidation replace healthcare reform?
• Paul
• 08th February, 16:42
• 0

• Cell Therapeutics lymphoma drug questioned by FDA
• Paul
• 08th February, 16:29
• 0

• FDA declines Zuplenz approval on travel restriction
• Paul
• 08th February, 16:17
• 0

• Pfizer rolls out eCard payment for medicines
• Paul
• 08th February, 10:12
• 0

• Recordati BPH drug approved by EC
• Paul
• 08th February, 09:08
• 0

• Pfizer partners with Qiagen for brain tumour diagnostic
• Paul
• 05th February, 16:55
• 0

• GSK narrows focus and cuts more jobs
• Paul
• 05th February, 08:31
• 0

• Drug discovery powered by Google?
• Paul
• 04th February, 06:32
• 0

• BMS in salary freeze
• Paul
• 04th February, 06:31
• 0

• GSK in $350m deal with Austrian biotech Apeiron
• Paul
• 04th February, 06:30
• 0

• Once-daily trazodone gets the FDA nod
• Paul
• 03rd February, 19:14
• 0

• Auxilium gets FDA approval for Xiaflex
• Paul
• 03rd February, 18:59
• 0

• Pfizer lowers expectations for 2010
• Paul
• 03rd February, 16:28
• 0

• Tamiflu drives record year for Roche
• Paul
• 03rd February, 10:51
• 0

• Lancet retracts MMR autism study
• Paul
• 02nd February, 17:12
• 0

• Spectrum licenses Belinostat from Topotarget
• Paul
• 02nd February, 16:47
• 0

• Hayfever treatment holds hope for dementia
• Paul
• 02nd February, 16:18
• 0

• Novo Nordisk raises 2010 forecast
• Paul
• 02nd February, 10:33
• 0

• Patent dispute costs Boston Scientific $1.7bn
• Paul
• 01st February, 16:57
• 0

• Call against ageism in clinical trials
• Paul
• 01st February, 16:54
• 0

• Cephalon buying Mepha for $590m
• Paul
• 01st February, 16:53
• 0

• Tykerb gets expanded use in breast cancer
• Paul
• 01st February, 10:52
• 0

• GSK cutting up to 4,000 jobs
• Paul
• 01st February, 10:40
• 0

• UCB pulls out of US primary care
• Paul
• 29th January, 17:35
• 0

• Gilead in $1bn stock buy back
• Paul
• 29th January, 16:27
• 0

• Bill and Melinda Gates Foundation pledges $10bn to vaccines
• Paul
• 29th January, 15:55
• 0

• BMS hunting for deals in 2010
• Paul
• 29th January, 10:14
• 0

• Lilly confirms view for 2010
• Paul
• 29th January, 10:04
• 0

• Nine drugmakers ruled as overcharging for medicines
• Paul
• 29th January, 09:48
• 0

• Icahn seeks three on the Biogen board
• Paul
• 28th January, 18:47
• 0

• AstraZeneca to cut 8,000 jobs
• Paul
• 28th January, 18:38
• 0

• Pfizer cleans out its pipeline
• Paul
• 28th January, 11:43
• 0

• Otsuka in possible $11bn IPO
• Paul
• 28th January, 11:31
• 0

• Herceptin approved by EC for stomach cancer
• Paul
• 28th January, 11:12
• 0

• Abbott forecast for 2010 raises expectations
• Paul
• 27th January, 19:38
• 0

• NICE recommends routine DVT hospital screening
• Paul
• 27th January, 11:01
• 0

• Teva wins first round in Temodar patent fight
• Paul
• 27th January, 10:51
• 0

• WHO defends handling of flu pandemic
• Paul
• 26th January, 16:41
• 0

• Novo Nordisk gets US approval for Victoza
• Paul
• 26th January, 10:47
• 0

• Jimenez to replace Vasella as Novartis CEO
• Paul
• 26th January, 10:35
• 0

• Democrats lose momentum on healthcare reform
• Paul
• 25th January, 16:31
• 0

• Quintiles launches new brand identity
• Paul
• 25th January, 16:12
• 0

• Pfizer files Sutent for pancreatic cancer
• Paul
• 25th January, 09:20
• 0

• FDA approves Acorda's MS drug
• Paul
• 25th January, 08:59
• 0

• CHMP gives positive opinion for Genmab’s Arzerra
• Paul
• 22nd January, 16:07
• 0

• Tysabri use to continue with new label
• Paul
• 22nd January, 15:57
• 0

• UCB gives Cimzia away to secure NICE approval
• Paul
• 22nd January, 08:52
• 0

• Anti-obesity drug sibutramine withdrawn
• Paul
• 22nd January, 08:39
• 0

• Vicriviroc fails late-stage trial for HIV
• Paul
• 21st January, 18:00
• 0

• Ipsen acquires 20 percent of Inspiration
• Paul
• 21st January, 17:49
• 0

• FDA says no to SkyePharma's Flutiform
• Paul
• 21st January, 17:26
• 0

• Novartis offer labelled “grossly inadequate” by Alcon
• Paul
• 21st January, 10:16
• 2

• Two pills offer new hope for multiple sclerosis
• Paul
• 21st January, 10:05
• 0

• GSK opens malaria database to researchers
• Paul
• 20th January, 16:40
• 0

• Victoza approved in Japan
• Paul
• 20th January, 16:28
• 0

• Study suggests England’s NHS is “most efficient” in UK
• Paul
• 20th January, 09:51
• 0

• Pfizer scans China for new partners
• Paul
• 20th January, 09:42
• 0

• Massachusetts threatens to derail healthcare reform
• Paul
• 20th January, 09:32
• 0

• Genvec hearing $220m deal with Novartis
• Paul
• 19th January, 16:45
• 0

• Forecast $10bn Indian biotech market by 2015
• Paul
• 19th January, 16:23
• 0

• Pfizer and Teva square up over Ratiopharm
• Paul
• 19th January, 16:13
• 0

• Study suggests global healthcare fraud costs €180bn
• Paul
• 18th January, 18:23
• 0

• Decline of swine flu hits big pharma sales
• Paul
• 18th January, 10:18
• 0

• Lawsuit raised against J&J alleging Omnicare kickbacks
• Paul
• 15th January, 16:33
• 0

• Use of bipolar drugs in young children doubles
• Paul
• 15th January, 16:19
• 0

• “Cadillac” tax gets the Democrats green light
• Paul
• 15th January, 10:15
• 0

• Concerns over rise of drug resistant HIV
• Paul
• 15th January, 10:00
• 0

• Pfizer contacted by EC over antitrust probe
• Paul
• 15th January, 09:48
• 0

• UK government abandons weekly flu briefings
• Paul
• 14th January, 10:35
• 0

• Merck submits new Gardasil data for older women
• Paul
• 14th January, 09:44
• 0

• Revlimid meets key endpoint in multiple myeloma trial
• Paul
• 13th January, 16:19
• 0

• Shionogi announces Rapiacta approval in Japan
• Paul
• 13th January, 09:49
• 0

• Study suggests ARBs may reduce risk of dementia
• Paul
• 13th January, 09:36
• 0

• FDA panel votes in favour of $159k per year Actelion drug
• Paul
• 13th January, 09:20
• 0

• EC expands antitrust investigations
• Paul
• 12th January, 19:35
• 0

• FDA panel rejects expanded use for Bystolic
• Paul
• 12th January, 19:18
• 0

• Alcon resists Novartis takeover
• Paul
• 12th January, 09:13
• 0

• GAO labels drug price rises extraordinary
• Paul
• 12th January, 08:56
• 0

• Second study not required for Levadex NDA submission
• Paul
• 11th January, 16:02
• 0

• Governments cut flu vaccine orders as threat wanes
• Paul
• 11th January, 10:13
• 0

• FDA approves Actemra for rheumatoid arthritis
• Paul
• 11th January, 09:49
• 0

• Kyowa licenses chronic kidney disease drug for $272m
• Paul
• 08th January, 16:38
• 0

• Cephalon 15 year veteran Robert Roche retires
• Paul
• 08th January, 16:05
• 0

• Teva plans to double revenue to $31bn by 2015
• Paul
• 08th January, 15:50
• 0

• Senate bill loophole could see insurance costs rise
• Paul
• 08th January, 09:55
• 0

• Billionaire investor Icahn takes aim at Genzyme
• Paul
• 08th January, 09:42
• 0

• AstraZeneca settles US patent disputes with Teva
• Paul
• 08th January, 09:28
• 0

• Pfizer collaborates with Debiopharm on melanoma drug
• Paul
• 07th January, 16:12
• 0

• EU antitrust investigation probes Lundbeck
• Paul
• 07th January, 15:57
• 0

• FDA scrutinizes Amgen and J&J anaemia drugs
• Paul
• 07th January, 09:46
• 0

• Pfizer collaborates with Strides to grow generics
• Paul
• 07th January, 09:30
• 0

• MannKind confident of FDA approval for inhaled insulin
• Paul
• 06th January, 15:33
• 0

• Public option unlikely to survive in US healthcare reform
• Paul
• 06th January, 09:11
• 0

• UK outlines plans to increase use of generics
• Paul
• 05th January, 15:47
• 0

• Genzyme outsources manufacturing to Hospira
• Paul
• 05th January, 15:37
• 0

• FDA approves expanded label for Velcade
• Paul
• 05th January, 15:27
• 0

• Federal judge approves $165m Clarinex settlement
• Paul
• 05th January, 15:11
• 0

• Biogen CEO to retire in June
• Paul
• 05th January, 08:33
• 0

• Dr. Reddy's announces positive results for phase III diabetes drug
• Paul
• 04th January, 17:24
• 0

• Novartis to fully acquire Alcon
• Paul
• 04th January, 09:21
• 0

• Clinical research declines in the UK
• Paul
• 31st December, 16:38
• 0

• FDA questions data for Basilea's superbug antibiotic
• Paul
• 30th December, 15:39
• 0

• Pfizer discontinues lung cancer trial
• Paul
• 30th December, 15:22
• 0

• J&J expands Tylenol recall
• Paul
• 29th December, 14:59
• 0

• Christmas news round up
• Paul
• 29th December, 11:37
• 0

• Senate passes healthcare reform bill
• Paul
• 24th December, 14:50
• 0

• Does Alzheimer's reduce cancer risk?
• Paul
• 24th December, 10:13
• 0

• NICE committee says no to Sanofi's Multaq
• Paul
• 24th December, 10:02
• 0

• AstraZeneca buys antibiotic developer Novexel
• Paul
• 24th December, 09:49
• 0

• Novartis in Corthera deal worth up to $620m
• Paul
• 23rd December, 16:07
• 0

• AstraZeneca recalls 4.7m doses of swine flu vaccine
• Paul
• 23rd December, 15:57
• 0

• Biovitrum licenses obesity drug to AstraZeneca
• Paul
• 22nd December, 15:35
• 0

• Incyte strikes autoimmune deal with Lilly
• Paul
• 21st December, 15:39
• 0

• Sanofi to buy Chattem for $1.9bn and enter US OTC market
• Paul
• 21st December, 15:27
• 0

• Sanofi discontinues two drugs, provides update
• Paul
• 21st December, 15:20
• 0

• EMEA recommends Prolia for approval
• Paul
• 21st December, 15:08
• 0

• NICE backs Yondelis for NHS use
• Paul
• 21st December, 10:40
• 0

• Astellas and Ambit strike $390m deal over FLT3 inhibitors
• Paul
• 18th December, 17:09
• 0

• Spiriva HandiHaler approved by FDA for COPD exacerbations
• Paul
• 18th December, 16:54
• 0

• Ark's Cerepro rejected, shares down
• Paul
• 18th December, 15:14
• 0

• GSK gets EU endorsement for Revolade approval
• Paul
• 18th December, 15:03
• 0

• Revlimid successful in transplant myeloma patients
• Paul
• 18th December, 14:55
• 0

• Taspoglutide goes head to head with Lantus
• Paul
• 17th December, 16:16
• 0

• J&J acquires Acclarent and sinus-surgery technology for $785m
• Paul
• 17th December, 16:00
• 0

• Biogen admits defeat, Facet seeks new buyers
• Paul
• 17th December, 15:44
• 0

• Tarceva fails to get FDA panel backing for earlier use
• Paul
• 17th December, 12:31
• 0

• Cancer genetic code cracked
• Paul
• 16th December, 18:34
• 0

• NICE gives Roche a warning over RoActemra
• Paul
• 16th December, 18:18
• 0

• Biogen ready for proxy fight for Facet
• Paul
• 16th December, 07:27
• 0

• Obama pushes for the finish with healthcare reform
• Paul
• 16th December, 07:18
• 0

• Gilead hypertension drug fails
• Paul
• 15th December, 16:16
• 0

• Pfizer and Takeda partner in China
• Paul
• 15th December, 09:57
• 0

• GSK reveals fees to US doctors
• Paul
• 15th December, 09:47
• 0

• Zyprexa Relprevv approved by FDA for schizophrenia
• Paul
• 14th December, 23:55
• 0

• Paxil lawsuits cost GSK "almost $1bn"
• Paul
• 14th December, 17:01
• 0

• Business sceptical of savings from US healthcare reform
• Paul
• 14th December, 15:27
• 0

• FDA allows Avastin breast cancer trial to continue
• Paul
• 14th December, 12:13
• 0

• Roche / Biogen arthritis drug effective in phase III study
• Paul
• 11th December, 18:42
• 0

• IMS sale threatened by potential data-mining ban
• Paul
• 11th December, 18:28
• 0

• Pfizer gets EU approval for Prevenar 13
• Paul
• 11th December, 18:15
• 0

• GSK demands further UK tax incentives
• Paul
• 11th December, 09:09
• 0

• Facet rejects Biogen's "best-and-final offer"
• Paul
• 10th December, 23:25
• 0

• Roche strengthens operations in Singapore
• Paul
• 10th December, 16:04
• 0

• GSK signals intent to lead rivals in emerging markets
• Paul
• 10th December, 15:04
• 0

• US healthcare reform considers Canadian imports
• Paul
• 10th December, 14:38
• 0

• Lilly plans two new launches a year
• Paul
• 10th December, 14:28
• 0

• Celgene data on Revlimid reveals unexpected downside
• Paul
• 09th December, 12:06
• 0

• Pfizer looks to the biogenerics market
• Paul
• 09th December, 11:56
• 0

• Ability of Tamiflu to prevent complications questioned
• Paul
• 09th December, 11:46
• 0

• FDA questions Gilead's cystic fibrosis drug
• Paul
• 08th December, 17:54
• 0

• Tasigna shows improved results over Glivec
• Paul
• 08th December, 16:34
• 0

• European enthusiasm for swine flu vaccine wanes
• Paul
• 08th December, 11:04
• 0

• Revlimid shows 50% cut in disease progression
• Paul
• 07th December, 23:34
• 0

• Amgen authorises $5bn share buyback
• Paul
• 07th December, 18:49
• 0

• Celgene acquires Gloucester Pharmaceuticals for up to $640m
• Paul
• 07th December, 15:45
• 0

• ASH data on Treanda – blockbuster potential ahead?
• Paul
• 07th December, 10:24
• 0

• BMS and Pfizer to seek EU approval for apixaban in 2010
• Paul
• 07th December, 10:06
• 0

• Concerns raised over atypical antipsychotics use in children
• Paul
• 04th December, 17:01
• 0

• AstraZeneca's Seroquel XR approved as adjunct for MDD by FDA
• Paul
• 04th December, 15:39
• 0

• FDA raises safety concerns over Merck, Novartis and GSK drugs
• Paul
• 04th December, 15:24
• 0

• Cephalon takes on Teva over Nuvigil patent
• Paul
• 03rd December, 15:52
• 0

• Targacept lands $1.24bn deal with AstraZeneca
• Paul
• 03rd December, 15:29
• 0

• Errors found in "1 in 10" UK hospital prescriptions
• Paul
• 03rd December, 12:23
• 0

• New stem cell lines approved in the US
• Paul
• 03rd December, 12:15
• 0

• Novartis wins EU approval for Onbrez Breezhaler
• Paul
• 03rd December, 12:02
• 0

• Roche hails phase III trial success for taspoglutide
• Paul
• 02nd December, 16:47
• 0

• UK doctors warned about Facebook use
• Paul
• 02nd December, 15:59
• 0

• Takeda positions for Indian market entry
• Paul
• 02nd December, 11:59
• 0

• FDA "refuse to file" Merck KGaA's oral MS treatment
• Paul
• 01st December, 17:48
• 0

• GSK takes stake in South African generics
• Paul
• 01st December, 17:29
• 0

• TEVA files for "generic filgrastim" in the US
• Paul
• 01st December, 17:20
• 0

• Cipla in generic supply talks with Pfizer
• Paul
• 01st December, 12:05
• 0

• PwC warns of tax rises for pharma
• Paul
• 01st December, 11:54
• 0

• Sanofi's Multaq approved in Europe
• Paul
• 30th November, 20:16
• 0

• Takeda ponders generics in emerging markets
• Paul
• 30th November, 20:04
• 0

• Revlimid predicted to triple sales on new data
• Paul
• 30th November, 19:54
• 0

• Debate for Democratic unity begins on healthcare bill
• Paul
• 30th November, 11:27
• 0

• GSK targets volume over margin in emerging markets
• Paul
• 30th November, 11:01
• 0

• Diabetes to double in US over 25 years, says study
• Paul
• 27th November, 13:48
• 0

• UK government asks doctors to go "full throttle" on flu vaccinations
• Paul
• 26th November, 17:46
• 0

• Incyte lands Novartis deal worth up to $1.1bn
• Paul
• 25th November, 17:50
• 0

• Pfizer expands R&D facilities in China
• Paul
• 25th November, 17:31
• 0

• Pharma sees the value in improved compliance
• Paul
• 25th November, 17:11
• 0

• Roche CEO confident of outgrowing the market
• Paul
• 25th November, 14:19
• 0

• NICE says no to Avastin use for bowel cancer
• Paul
• 24th November, 20:17
• 0

• Study suggests Vioxx risks apparent years before withdrawal
• Paul
• 24th November, 09:03
• 0

• Viehbacher outlines strategy for Sanofi-Aventis
• Paul
• 24th November, 08:36
• 1

• US Senate approves move to debate healthcare bill
• Paul
• 23rd November, 09:09
• 0

• AZ could face 6,000 lawsuits over Seroquel
• Paul
• 21st November, 08:38
• 1

• Oncophage cancer vaccine rejected by EMEA
• Paul
• 20th November, 16:57
• 0

• Drug resistant strain of swine flu on the way?
• Paul
• 20th November, 15:06
• 0

• EMEA backs single dose swine flu vaccine
• Paul
• 20th November, 14:55
• 0

• Pfizer sees generics as a route to being big in Japan
• Paul
• 19th November, 10:25
• 0

• AstraZeneca submits Brilinta for approval in the US
• Paul
• 19th November, 10:13
• 0

• NICE rejects Nexavar for kidney cancer
• Paul
• 19th November, 10:03
• 0

• Senate unveils healthcare bill
• Paul
• 19th November, 09:47
• 0

• Brilinta data versus Plavix suggests a bright future
• Paul
• 19th November, 09:26
• 1

• Qiagen still on the diagnostics acquisition trail
• Paul
• 18th November, 16:28
• 0

• Rollercoaster week for Genzyme continues as it drops Renvela successor
• Paul
• 18th November, 15:23
• 0

• FDA warning over Plavix-Prilosec combination
• Paul
• 18th November, 12:52
• 0

• UCB reorganises with potential job losses
• Paul
• 17th November, 16:26
• 0

• Mipomersen results mark upturn in seesaw week for Genzyme
• Paul
• 17th November, 16:17
• 0

• Flibanserin hailed as "Viagra for women"
• Paul
• 17th November, 15:52
• 0

• Study shows cardiac arrest patients should keep a cool head
• Paul
• 16th November, 19:08
• 0

• GSK licenses nicotine addiction vaccine
• Paul
• 16th November, 15:28
• 0

• ARBITER study questions Zetia, Merck responds
• Paul
• 16th November, 14:26
• 0

• GSK turns attention to the environment
• Paul
• 16th November, 14:06
• 0

• No protection from seasonal flu vaccine against H1N1
• Paul
• 13th November, 16:54
• 0

• FDA reviews impact of social media on pharma
• Paul
• 13th November, 16:20
• 0

• Lilly poaches AstraZeneca’s Head of Drug Discovery
• Paul
• 13th November, 15:47
• 0

• Review suggests overuse of dementia drugs could be contributing to deaths
• Paul
• 12th November, 18:48
• 0

• Pfizer in the spotlight over Neurontin data
• Paul
• 12th November, 09:36
• 0

• Job losses as GSK integrates Stiefel operations
• Paul
• 11th November, 17:22
• 0

• New European warning over flu
• Paul
• 11th November, 16:31
• 0

• GSK donates flu vaccine to the WHO
• Paul
• 10th November, 15:50
• 0

• Pfizer starts streamlining new organisation
• Paul
• 10th November, 15:38
• 0

• New warning over antibiotic overuse
• Paul
• 09th November, 18:32
• 1

• Tysabri label change due to PML risk
• Paul
• 09th November, 15:16
• 0

• Obama squeezes $1 trillion health bill through the House
• Paul
• 09th November, 10:27
• 0

• [sticky] How to post comments on the site
• Paul
• 07th November, 17:48
• 0

• TPG & CPP buys IMS Health for $4bn
• Paul
• 06th November, 16:15
• 1

• Dutch authorities recall Prevenar batch
• Paul
• 06th November, 09:46
• 0

• FDA turns its eye to drug compliance and misuse
• Paul
• 05th November, 12:25
• 0

• Merck KGaA gambles on breast cancer vaccine
• Paul
• 04th November, 15:33
• 0

• Novartis looks to China for new opportunities
• Paul
• 04th November, 10:03
• 0

• J&J to lose around 7,000 jobs
• Paul
• 03rd November, 13:15
• 0

• Takeda and Amylin sign obesity deal worth up to $1bn
• Paul
• 02nd November, 16:42
• 0

• GSK / Human Genome lupus drug gets closer to market
• Paul
• 02nd November, 11:23
• 0

• Eli Lilly opens new "biotechnology powerhouse"
• Paul
• 30th October, 17:00
• 0

• AstraZeneca ready to make $520m Seroquel settlement
• Paul
• 30th October, 15:55
• 1

• Swine flu second wave starts to break
• Paul
• 29th October, 15:56
• 0

• Pfizer Execs get seven figure bonuses for Wyeth acquisition
• Paul
• 29th October, 15:42
• 0

• British charitable trust sues over Enbrel patent
• Paul
• 28th October, 17:45
• 0

• AstraZeneca withdraws Zactima regulatory submissions
• Paul
• 28th October, 17:23
• 0

• Genmab gains first FDA approval with Arzerra
• Paul
• 27th October, 16:01
• 0

• J&J seeks alliances with rivals to manage risk
• Paul
• 26th October, 14:33
• 0

• FDA reaffirms exclusivity for Shire's Vyvanse
• Paul
• 26th October, 14:22
• 0

• Disease diagnosis correction from genome analysis
• gs
• 24th October, 18:09
• 1

• Pfizer may be looking to India for new revenue growth
• Paul
• 23rd October, 15:21
• 0

• New safety review on Tysabri hits Elan and Biogen
• Paul
• 23rd October, 15:04
• 0

• Sepracor acquisition could land CEO $11m payout
• Paul
• 22nd October, 16:25
• 1

• Promising results for Isis Pharma's antisense diabetes drug
• Paul
• 22nd October, 15:16
• 1

• Sanofi-Aventis buys Wellstat diabetes drug
• Paul
• 21st October, 14:26
• 0

• Genzyme Q3 profits down 87% due to manufacturing issues
• Paul
• 21st October, 14:17
• 0

• FDA approves GSK's Votrient for renal cancer
• Paul
• 20th October, 14:32
• 0

• Pfizer fined $1.3bn over Bextra
• Paul
• 20th October, 10:41
• 1

• IMS up for sale?
• Paul
• 20th October, 07:44
• 0

• FDA approves Cervarix and Gardasil
• Paul
• 19th October, 14:53
• 0

• FDA approves Crestor for new indication in children
• Paul
• 16th October, 14:12
• 0

• GSK and AZ see approvals in Japan
• Paul
• 16th October, 14:08
• 0

• Pfizer receives US and Canadian approval for Wyeth acquisition
• Paul
• 14th October, 20:25
• 0

• Progenics regains Relistor rights from Wyeth
• Paul
• 14th October, 20:17
• 0

• Acorda Therapeutics stock trading halted
• Paul
• 14th October, 16:27
• 0

• Galapagos expands Merck alliance
• Paul
• 14th October, 16:20
• 0

• GSK pays up to $679m in rare disease deal
• Paul
• 13th October, 14:31
• 0

• Novartis acquires US and Canadian rights for Fanapt
• Paul
• 13th October, 14:23
• 0

• Onyx to acquire Proteolix
• Paul
• 12th October, 18:14
• 0

• Pfizer halts late-stage figitumumab lung cancer trial over safety concerns
• Paul
• 12th October, 08:04
• 0

• Chronic fatigue syndrome virus discovery
• Paul
• 09th October, 15:18
• 0

• IMS Health raises global pharma growth expectations for 2010
• Paul
• 09th October, 15:09
• 0

• Hospira signs biogeneric deal with Celltrion
• Paul
• 09th October, 14:59
• 0

• OXiGENE announces resignation of CEO
• Paul
• 09th October, 14:50
• 0

• FDA investigating drug safety risks
• Paul
• 08th October, 15:22
• 0

• Labopharm announces Tramadol agreement with Grunenthal
• Paul
• 08th October, 15:14
• 0

• FDA approves Welchol for additional indication
• Paul
• 07th October, 14:18
• 0

• EC conducts raids over suspected antitrust violations
• Paul
• 07th October, 13:59
• 0

• GSK announces global flu vaccine stockpiling
• Paul
• 06th October, 17:47
• 0

• EC approves Onglyza for type 2 diabetes in Europe
• Paul
• 06th October, 06:48
• 0

• Chromosome research wins Nobel prize
• Paul
• 05th October, 14:36
• 0

• Actavis launches generic atorvastatin in Spain
• Paul
• 02nd October, 14:59
• 0

• Dapagliflozin hits study target
• Paul
• 02nd October, 14:30
• 0

• Sanofi-Aventis to acquire Fovea
• Paul
• 01st October, 13:55
• 0

• Takeda expanding Western operations
• Paul
• 01st October, 13:48
• 0

• Hospira acquires global rights to biogeneric filgrastim
• Paul
• 30th September, 17:34
• 0

• Sanofi-Aventis shopping for acquisitions
• Paul
• 30th September, 16:52
• 0

• Pfizer merger gets Australian approval
• Paul
• 30th September, 14:17
• 0

• J&J enters strategic collaboration with Crucell
• Paul
• 28th September, 18:05
• 0

• GSK signs $2.2bn vaccine deal with Brazil
• Paul
• 28th September, 13:48
• 0

• Abbott to acquire Solvay Pharmaceuticals
• Paul
• 28th September, 07:56
• 0

• FDA approves additional protection for Flomax
• Paul
• 25th September, 14:23
• 0

• Eisai to co-promote Lyrica in Japan
• Paul
• 25th September, 14:17
• 0

• EMEA recommends approval for swine flu vaccines
• Paul
• 25th September, 14:11
• 0

• Boehringer Ingelheim eliminates 600+ sales roles
• Paul
• 25th September, 12:24
• 4

• Abbott interested in Solvay Pharmaceuticals
• Paul
• 24th September, 14:49
• 0

• Cell Therapeutics withdraws EU application for Opaxio
• Paul
• 24th September, 14:45
• 0

• QIAGEN acquires DxS Ltd.
• Paul
• 23rd September, 17:08
• 0

• Novo Nordisk announces delay on liraglutide feedback from FDA
• Paul
• 23rd September, 16:10
• 0

• LEO Pharma reacquires US product rights from Warner Chilcott
• Paul
• 23rd September, 16:02
• 0

• Facet advises shareholders to take no action on Biogen Idec bid
• Paul
• 22nd September, 19:22
• 0

• Nektar signs $1bn+ licensing deal with AstraZeneca
• Paul
• 21st September, 14:30
• 0

• Sanofi-Aventis completes Merial acquisition
• Paul
• 18th September, 14:19
• 0

• Nycomed made 4bn Euro bid for Solvay Pharmaceuticals
• Paul
• 18th September, 14:12
• 0

• Novartis gets FDA approval for Valturna
• Paul
• 18th September, 12:25
• 0

• Renovo announces job cuts as takeover disappears
• Paul
• 17th September, 14:35
• 0

• FDA approves four new H1N1 flu vaccines
• Paul
• 16th September, 13:48
• 0

• BMS in Asia deal with Taisho
• Paul
• 16th September, 13:40
• 0

• Thermo Fisher Scientific appoints new CEO
• Paul
• 15th September, 14:25
• 0

• Bayer announces new CEO
• Paul
• 15th September, 14:14
• 0

• Lilly announces cost savings program
• Paul
• 14th September, 17:36
• 0

• Nycomed could be closing in on Solvay deal
• Paul
• 14th September, 07:48
• 0

• Dr Reddy's refutes stake sale
• Paul
• 11th September, 13:37
• 0

• NICE rejects Nexavar again
• Paul
• 09th September, 15:13
• 0

• Roche announces new corporate structure
• Paul
• 08th September, 18:58
• 0

• Facet rejects Biogen Idec bid
• Paul
• 08th September, 14:20
• 0

• Sinopharm to raise up to $1.13bn in IPO
• Paul
• 07th September, 12:30
• 0

• ZEVALIN approved for expanded label in NHL
• Paul
• 07th September, 10:55
• 0

• Dainippon in $2.6bn acquisition of Sepracor
• Paul
• 04th September, 12:00
• 0

• LEO Pharma to acquire Peplin for US $287.5m
• Paul
• 03rd September, 13:46
• 0

• Pfizer in $2.3bn settlement over marketing charges
• Paul
• 02nd September, 15:28
• 0

• Depression to become "leading" illness within 20 years
• Paul
• 02nd September, 12:33
• 0

• Affitech A/S appoints Dr. Robert Burns as CEO
• Paul
• 01st September, 15:10
• 0

• Merck and Co announces new corporate structure
• Paul
• 31st August, 13:54
• 0

• CEO of LifeCycle Pharma steps down with immediate effect
• Paul
• 31st August, 13:40
• 0

• FDA approves Eurand's Zenpep
• Paul
• 28th August, 15:03
• 0

• [sticky] Read this first - welcome to the forum
• Paul
• 26th August, 12:55
• 0

New Topic in this Forum

You must log in to post.